Series B · Biotech
Ollin Biosciences: Series B
Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD
Funding history
Series B · This round$330M
Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD